Moleculin Biotech Inc. [NASDAQ: MBRX] gained 1.93% or 0.07 points to close at $3.69 with a heavy trading volume of 13202600 shares. The company report on April 14, 2021 that Moleculin Awarded New Rare Pediatric Disease Designation from U.S. FDA for WP1066 for the Treatment of Ependymoma.
Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation (RPD) to its p-STAT3 inhibitor, WP1066, for the treatment of ependymoma.
Ependymoma is a rare type of tumor that can form in the brain or spinal cord. Ependymoma begins in the ependymal cells in the brain and spinal cord that line the passageways where the fluid (cerebrospinal fluid) that nourishes your brain flows. Ependymoma can occur at any age, but most often occurs in young children.
It opened the trading session at $3.90, the shares rose to $3.97 and dropped to $3.60, the range by which the price of stock traded the whole day. The daily chart for MBRX points out that the company has recorded -25.53% loss over the past six months. However, it is still -16.77% lower than its most recent low trading price.
If we look at the average trading volume of 3.05M shares, MBRX reached to a volume of 13202600 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Moleculin Biotech Inc. [MBRX]:
The Average True Range (ATR) for Moleculin Biotech Inc. is set at 0.27 The Price to Book ratio for the last quarter was 0.06, with the Price to Cash per share for the same quarter was set at 0.52.
Trading performance analysis for MBRX stock
Moleculin Biotech Inc. [MBRX] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -4.40. With this latest performance, MBRX shares dropped by -17.45% in over the last four-week period, additionally sinking by -25.53% over the last 6 months – not to mention a drop of -5.38% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for MBRX stock in for the last two-week period is set at 39.88, with the RSI for the last a single of trading hit 38.51, and the three-weeks RSI is set at 41.16 for Moleculin Biotech Inc. [MBRX]. The present Moving Average for the last 50 days of trading for this stock 4.35, while it was recorded at 3.71 for the last single week of trading, and 5.05 for the last 200 days.
Moleculin Biotech Inc. [MBRX]: A deeper dive into fundamental analysis
Return on Total Capital for MBRX is now -115.73, given the latest momentum, and Return on Invested Capital for the company is -102.40. Return on Equity for this stock declined to -103.74, with Return on Assets sitting at -63.81. When it comes to the capital structure of this company, Moleculin Biotech Inc. [MBRX] has a Total Debt to Total Equity ratio set at 1.55. Additionally, MBRX Total Debt to Total Capital is recorded at 1.52, with Total Debt to Total Assets ending up at 0.95. Long-Term Debt to Equity for the company is recorded at 0.89, with the Long-Term Debt to Total Capital now at 0.88.
Reflecting on the efficiency of the workforce at the company, Moleculin Biotech Inc. [MBRX] managed to generate an average of -$1,157,000 per employee.Moleculin Biotech Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 5.90 and a Current Ratio set at 5.90.
Moleculin Biotech Inc. [MBRX]: An earnings per share (EPS) analysis
With the latest financial reports released by the company, Moleculin Biotech Inc. posted -0.12/share EPS, while the average EPS was predicted by analysts to be reported at -0.6/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 80.00%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for MBRX.
An analysis of insider ownership at Moleculin Biotech Inc. [MBRX]
There are presently around $2 million, or 7.70% of MBRX stock, in the hands of institutional investors. The top three institutional holders of MBRX stocks are: RENAISSANCE TECHNOLOGIES LLC with ownership of 158,087, which is approximately 6.437% of the company’s market cap and around 4.09% of the total institutional ownership; VANGUARD GROUP INC, holding 98,661 shares of the stock with an approximate value of $0.36 million in MBRX stocks shares; and GEODE CAPITAL MANAGEMENT, LLC, currently with $0.18 million in MBRX stock with ownership of nearly 23.387% of the company’s market capitalization.
Positions in Moleculin Biotech Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 13 institutional holders increased their position in Moleculin Biotech Inc. [NASDAQ:MBRX] by around 43,352 shares. Additionally, 10 investors decreased positions by around 98,968 shares, while 8 investors held positions by with 294,121 shares. The mentioned changes placed institutional holdings at 436,441 shares, according to the latest SEC report filing. MBRX stock had 11 new institutional investments in for a total of 24,433 shares, while 3 institutional investors sold positions of 35,209 shares during the same period.